Navigation Links
Echo Therapeutics Reports Third Quarter 2007 Results
Date:11/20/2007

488,650 103,365

Total current liabilities 915,248 284,823

Notes Payable, net of current portion - 54,508

Commitments

Stockholders' Equity

Series A Convertible Preferred Stock,

$0.01 par value, authorized

7,000,000 shares, issued and

outstanding no shares at

September 30, 2007 and 73,334

shares at December 31, 2006 - 76,291

Common stock, $0.01 par value,

authorized 60,000,000 shares,

issued and outstanding

17,707,679 shares at September

30, 2007 and 2,776,192 shares

at December 31, 2006 177,079 27,762

Additional paid-in capital 56,494,899 34,822,306

Accumulated deficit (44,738,545) (34,460,661)

Total stockholders' equity 11,933,433 465,698

Total liabilities and

stockholders' equity $12,848,681 $805,029

Echo Therapeutics, Inc.

(Formerly Sontra Medical Corporation)

Consolidated Statements of Operations

(Unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2007 2006 2007 2006

Revenue:

Product revenues $ - $10,679 $12,120 $37,619

Licensing revenue 12,500 12,500 37,500 37,501

Total revenue 12,500 23,179 49,620 75,120

Operating Expenses:

Cost of product

revenue - 9,445 1,556 61,734

Research and

development
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 19, 2014 Research and Markets ... of the "Technology Innovations in Smart Fabrics ... http://photos.prnewswire.com/prnh/20130307/600769 ... Fabrics" offers a detailed assessment on technological advancements ... Findings: 1. The Smart Fabrics ...
(Date:12/19/2014)... December 18, 2014 LayerBio is an ... and wound care. The National Eye Institute (NEI) at ... a Phase I SBIR grant to develop a drug-eluting ... the most common cause of vision loss in people ... worldwide. According to Dr. Ken Mandell, LayerBio’s Founder and ...
(Date:12/19/2014)... December 18, 2014 iLab Solutions, the ... appointment of Siri Bryant as the new Director of ... of Core Implementations. These two new leadership positions were ... service by ensuring that iLab continues to meet the ... last four years, iLab has been deployed at over ...
(Date:12/19/2014)... 18, 2014 With only 2 weeks ... special on Sartorius Biohit products . The product specials ... Picus Electronic Pipette Trade-in Program, and free pipette tips. ... officers around the world. They are ideal for lab ... include:, ,     Full volume range of 0.1 ...
Breaking Biology Technology:Technology Innovations in Smart Fabrics (Technical Insights) 2LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2
... eResearchTechnology,Inc. (eRT), (Nasdaq: ERES ), a leading ... today that it will release its 2008 first ... on Monday, May 5,2008 after the market closes.,After ... call at 5:00 PM ET,later that day., ...
... - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today ... St. James,s University Hospital in Leeds,U.K. published the ... May 1, 2008,online issue of The Journal of ... Cells to Promote Innate Antitumor Immunity.", The ...
... April 23 SectorWatch.biz announces the,availability of ... and driving,markets today within the biotechnology and ... the aforementioned equities and the,opportunity for investors ... the,subject and sector., Investors can view ...
Cached Biology Technology:eResearchTechnology, Inc. to Announce 2008 First Quarter Results on May 5, 2008 2Oncolytics Biotech Inc. Announces Journal of Immunology Publication on Reovirus Activation of Dendritic Cells 2SectorWatch.biz Issues MarketStats on KBLB, DGX, LH, BRLI, and ABT 2SectorWatch.biz Issues MarketStats on KBLB, DGX, LH, BRLI, and ABT 3
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a ... $2.3 million in Series A1 funding led by UK-based ... also participated in the investment round. "We ... healthcare community adopts next-generation sequencing and seeks new approaches ... Reid Robison , MD MBA, and CEO of ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... York College, and one of the most prolific inventors ... that are transmitted from Smartphones to third party agencies. ... and has one of the earliest known patents in ... usage in the military, child care, elder care and ...
(Date:11/18/2014)... , Nov. 17, 2014   ... and EMC collaborate to develop The Partners Data ... , The Partners Data Lake will allow researcher ... improve diagnostics, treatment and the lives of patients ... research and clinical activities across the Partners system, ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... A team of cardiologists, materials scientists, and bioengineers ... device for measuring the heart,s electrical output that they ... new device represents the first use of flexible silicon ... believe that this technology may herald a new generation ...
... ngeles Mena, Researcher at Centro de Investigacin Biomdica ... of the Neuropharmacology Laboratory at Hospital Ramn y ... predoctoral student Juan Perucho and others. The ... changes and amyloid pathology of Alzheimer,s disease in ...
... PITTSBURGH, March 24 An experimental vaccine against an ... delay the onset of inflammatory bowel disease (IBD) and in ... the University of Pittsburgh School of Medicine. Their findings are ... journal of the American Association for Cancer Research. People ...
Cached Biology News:New tissue-hugging implant maps heart electrical activity in unprecedented detail 2New tissue-hugging implant maps heart electrical activity in unprecedented detail 3Anesthesia increases risk of developing Alzheimer's disease in patients with genetic predisposition 2Anesthesia increases risk of developing Alzheimer's disease in patients with genetic predisposition 3Vaccine could delay bowel inflammation and colon cancer, says Pitt research 2
C/EBPalpha Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
Goat polyclonal to FBXO2 ( Abpromise for all tested applications). entrezGeneID: 26232 SwissProtID: Q9UK22...
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
Biology Products: